262 related articles for article (PubMed ID: 29791895)
61. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
62. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
63. High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study.
Bajbouj M; Becker V; Phillip V; Wilhelm D; Schmid RM; Meining A
Digestion; 2009; 80(2):112-8. PubMed ID: 19641320
[TBL] [Abstract][Full Text] [Related]
64. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
65. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
Johnson D; Crawley JA; Hwang C; Brown K
Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
[TBL] [Abstract][Full Text] [Related]
66. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
67. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
68. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
[TBL] [Abstract][Full Text] [Related]
69. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor.
Jones R; Patrikios T
Int J Clin Pract; 2008 Dec; 62(12):1844-50. PubMed ID: 19166433
[TBL] [Abstract][Full Text] [Related]
70. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
[TBL] [Abstract][Full Text] [Related]
71. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease.
Velanovich V
J Gastrointest Surg; 1998; 2(2):141-5. PubMed ID: 9834409
[TBL] [Abstract][Full Text] [Related]
72. Longitudinal study of gastroesophageal reflux and erosive tooth wear.
Wilder-Smith CH; Materna A; Martig L; Lussi A
BMC Gastroenterol; 2017 Oct; 17(1):113. PubMed ID: 29070010
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.
Yu YY; Fang DC; Fan LL; Chang H; Wu ZL; Cao Y; Lan CH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1200-6. PubMed ID: 24955450
[TBL] [Abstract][Full Text] [Related]
74. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
[TBL] [Abstract][Full Text] [Related]
75. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q; Wang R; Liu L; Zhao F; Wang S
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):803-10. PubMed ID: 26329348
[TBL] [Abstract][Full Text] [Related]
76. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
[TBL] [Abstract][Full Text] [Related]
77. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
[TBL] [Abstract][Full Text] [Related]
78. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
79. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial.
Moayyedi P; Armstrong D; Hunt RH; Lei Y; Bukoski M; White RJ
Am J Gastroenterol; 2010 Nov; 105(11):2341-6. PubMed ID: 20842110
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms: a meta-analysis.
Mei J; Yu Y; Ma J; Yu X
Pharmazie; 2016 May; 71(5):285-91. PubMed ID: 27348974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
